



ASX release

14 October 2015

Appointment of new director

AtCor Medical Holdings Limited (ASX:ACG), the developer and marketer of the SphygmoCor[®] system which measures central aortic blood pressures and arterial stiffness non-invasively, today announced the retirement of Peter Jenkins as a Director at the next Annual General Meeting and the appointment of his replacement, King Nelson.

Peter Jenkins has decided not to seek re-election at the Annual General Meeting to be held on 13 November 2015 after 16 years as a non-executive Director. Peter initially joined AtCor's Board in 1999, before AtCor was listed, as a representative of Hambro Grantham, one of the venture capital firms that provided initial funding to AtCor, and served as the company's Chairman for four years until 2003. Following AtCor's listing on ASX in 2005 he continued as an independent Director having retired from Colonial First State Private Equity, the new owners of Hambro Grantham. He has held the position of Chairman of the Nomination & Remuneration Committee for the last 10 years and has served as a member of the Audit & Risk Committee.

Donal O'Dwyer, AtCor's Chairman, said: "Peter has served on the AtCor Board with distinction for a long period of time and has helped set the company up for a bright future. I have always valued his counsel and he can be proud of the company he leaves behind. We wish him well in his retirement."

The Board has nominated Randall King Nelson as Peter's replacement. He will be an independent non-executive Director.

King, who is based in California, has more than 30 years' experience in the medical devices industry. He is currently President and CEO of Uptake Medical Corporation, a company focused on treatments for emphysema and lung cancer. Previously, he served as president and CEO of Kerberos Proximal Solutions, which was acquired by FoxHollow Technologies; and as president and CEO of VenPro, a heart valve business acquired by Medtronic. Prior to that, he spent 19 years with Baxter International and American Hospital Supply Corporation in roles of increasing responsibility that included division president for Dade Diagnostics, Bentley Labs, and Baxter's Perfusion Services.

Mr Nelson also served as chairman of Digirad Corporation (NASDAQ: DRAD) from 2003 to 2012.

Donal O'Dwyer commented: "We are delighted to have a director of King's calibre seek to join our Board. AtCor is entering a new exciting phase in its journey towards becoming a larger company and King brings a deep understanding of, and experience in, the markets we will be pursuing."

About AtCor Medical

AtCor Medical develops and markets products for the early detection of cardiovascular risk and management of cardiovascular disease. Its technology allows researchers and clinicians to measure central aortic blood pressure non-invasively. The company's SphygmoCor[®] system visibly identifies the effects of reflected blood pressure in the central aortic pressure wave, effects which cannot be detected with standard blood pressure monitoring. More than 3,800 SphygmoCor[®] systems are currently in use worldwide at major medical institutions, research institutions and in various clinical trials with leading pharmaceutical companies. The company's technology has been featured in over 900 peer-reviewed studies published in leading medical journals and thousands of citations. AtCor has operations in Australia, the United States, and Europe. For further information, please visit our web site at www.atcormedical.com.

For further information, please contact

Duncan Ross – AtCor Medical CEO
+1 (630) 228 8873

Peter Manley – AtCor Medical CFO
+61 (2) 8815 8811

Media enquiries to:

Ashley Rambukwella – Financial &
Corporate Relations
Ph: +61 (2) 8264 1004/ m. 0407 231 282 or
a.rambukwella@fcr.com.au